Should I Buy Medibank Private Stock in Australia in 2025?
Is it the right time to buy Medibank Private?
ScoreMedibank Private Limited (ASX: MPL) stands out among Australian health insurers, offering both stability and steady growth in a sector vital to the nation’s well-being. As of July 2025, MPL shares are trading near $4.97, with an average daily trading volume of approximately 6.94 million shares, highlighting consistent interest from investors. The company has recently delivered robust half-year results, with revenues up by 6.1% and operating profit growing by 12.5%, exceeding analyst expectations. This performance supported a new 52-week high of $5.31 at the start of July, and the market’s constructive reaction to the latest dividend payout underlines Medibank’s appeal for income-focused investors. While rising healthcare costs and growing competition present manageable challenges, the outlook remains positive, supported by Medibank’s leadership in digital health innovation and commitment to sustainability. The broader private health insurance sector in Australia is forecasted for ongoing growth, further buoying sentiment. Drawing on the consensus target price of $6.46 set by more than 13 leading national and global banks, Medibank Private is well-placed for those seeking a combination of income and potential capital appreciation.
- ✅Sector-leading position in private health insurance in Australia.
- ✅Consistent revenue and operating profit growth above market averages.
- ✅Attractive dividend yield with fully franked payouts.
- ✅Strong balance sheet and low share price volatility.
- ✅Ongoing digital innovation and expansion in telehealth services.
- ❌Healthcare cost inflation may pressure profit margins over time.
- ❌Increasing competition may temper future market share gains.
Score- ✅Sector-leading position in private health insurance in Australia.
- ✅Consistent revenue and operating profit growth above market averages.
- ✅Attractive dividend yield with fully franked payouts.
- ✅Strong balance sheet and low share price volatility.
- ✅Ongoing digital innovation and expansion in telehealth services.
Is it the right time to buy Medibank Private?
- ✅Sector-leading position in private health insurance in Australia.
- ✅Consistent revenue and operating profit growth above market averages.
- ✅Attractive dividend yield with fully franked payouts.
- ✅Strong balance sheet and low share price volatility.
- ✅Ongoing digital innovation and expansion in telehealth services.
- ❌Healthcare cost inflation may pressure profit margins over time.
- ❌Increasing competition may temper future market share gains.
Score- ✅Sector-leading position in private health insurance in Australia.
- ✅Consistent revenue and operating profit growth above market averages.
- ✅Attractive dividend yield with fully franked payouts.
- ✅Strong balance sheet and low share price volatility.
- ✅Ongoing digital innovation and expansion in telehealth services.
- What is Medibank Private?
- The price of Medibank Private stock
- Our full analysis of the Medibank Private stock
- How to buy Medibank Private stock in Australia
- Our 7 tips for buying Medibank Private stock
- The latest news about Medibank Private
- FAQ
Why trust HelloSafe ?
At HelloSafe, our expert has been tracking the performance of Medibank Private for over three years. Every month, hundreds of thousands of users in Australia trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, paid by Medibank Private.
What is Medibank Private?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Australia | Key player in Australia’s health insurance and digital health. |
| 💼 Market | ASX | Listed on the main Australian stock exchange. |
| 🏛️ ISIN code | AU000000MPL3 | Global securities identifier for Medibank Private shares. |
| 👤 CEO | David Koczkar | Leading digital transformation and growth strategy. |
| 🏢 Market cap | AUD 13.69 billion | Reflects Medibank Private's strong sector position. |
| 📈 Revenue | AUD 4.27 billion (H1 2025) | Revenue shows steady growth and strong customer retention. |
| 💹 EBITDA | AUD 386.8 million (H1 2025) | EBITDA growth outpaced revenue, signalling efficiency gains. |
| 📊 P/E Ratio (Price/Earnings) | 27.95 | Indicates healthy investor confidence in future earnings. |
The price of Medibank Private stock
The price of Medibank Private stock is falling this week. The current share price is AUD 4.97, down 1.78% over the past 24 hours and 0.60% lower for the week. Medibank Private’s market capitalisation stands at AUD 13.69 billion, with an average daily volume of 6.94 million shares (3-month average). The stock trades at a P/E ratio of 27.95 and offers a dividend yield of 3.28%. The beta is just 0.12, indicating very low volatility in comparison to the broader market. This stability highlights Medibank Private as a solid option for cautious investors seeking steady returns.
Our full analysis of the Medibank Private stock
We have conducted a comprehensive review of Medibank Private’s latest financial results, evaluated the stock’s performance over the past three years, and synthesised a broad spectrum of expert analysis—from market indicators to technical signals and peer benchmarks—using our proprietary assessment algorithms. In a rapidly evolving healthcare and digital innovation landscape, Medibank Private continues to command the attention of both institutional and retail investors. So, why might Medibank Private stock once again become a strategic entry point into the health insurance and digital healthcare sector in 2025?
Recent performance and market context
Medibank Private’s share price has demonstrated robust momentum, rising by +30.10% over the past six months and an impressive +37.29% over the last twelve months, currently trading at AUD 4.97 (3 July 2025). This upward trajectory highlights a phase of renewed market confidence and delivers one of the sector’s best performances in 2025. Landmark outcomes such as a record 52-week high of AUD 5.31 (July 2025) and resilient daily trading activity signal persistent institutional demand.
The broader Australian health insurance sector remains structurally attractive: robust population growth, strong migration trends, and rising spending on private health cover provide tailwinds for Medibank Private. Notably, the company’s recent semi-annual results (H1 2025) exceeded analyst expectations—even as some costs remain under inflationary pressure—by delivering strong operational profit growth and steady revenue expansion. The defensive nature of healthcare, combined with digital service innovation, offers a favourable context for investors seeking both stability and growth exposure.
Technical analysis
From a technical analysis standpoint, Medibank Private is positioned in a clear bullish configuration. The 14-day RSI stands at 54.23—firmly in neutral-to-positive territory and well clear of any overbought risk—while the MACD remains above signal at +0.07, confirming a persistent buy signal on momentum oscillators.
Perhaps most compelling, every major moving average (20, 50, 100, 200 days) is currently acting as dynamic support, not resistance, underpinning a powerful Golden Cross set-up. The share price breaking through short- and medium-term resistance levels, with a solid floor at AUD 4.86 and an upper target at AUD 5.16, hints at continued upward potential. All technical signals suggest that the short- and medium-term structure favours further advances, making current market levels especially attractive for strategic entry.
Fundamental analysis
Fundamentally, Medibank Private’s growth engine remains resilient and diversified. H1 2025 revenues clocked in at AUD 4.27 billion, up +6.1% year-on-year, accompanied by a 12.5% increase in operating profit—demonstrating not just revenue expansion, but also effective cost management and margin preservation, despite inflationary headwinds. Net profit remains healthy at AUD 340.3 million, and the company maintains its longstanding policy of regular dividend payouts (current yield is 3.28%), reinforcing the investment’s income attributes.
With a Price/Earnings ratio of 27.95, the stock’s valuation may appear elevated, but it is adequately justified by a projected 9% compound annual earnings growth rate and a consistently above-market return profile. Medibank Private’s ongoing digital transformation, expansion into telemedicine, and robust market share all point to structural advantages that should anchor future growth. Its strong brand loyalty and regulatory adaptability further support its premium valuation.
Volume and liquidity
Medibank Private’s sustained average trading volume—6.94 million shares daily (3-month average)—underscores deep market liquidity and sustained investor commitment. The free float of 2.75 billion shares ensures dynamic price discovery and steady supply/demand balance. This degree of liquidity is highly favourable for both institutional allocation and nimble retail entry, as it minimises transaction costs and facilitates efficient execution, even at scale.
Catalysts and positive outlook
Several powerful catalysts reinforce the positive trajectory for Medibank Private. The company’s aggressive expansion into digital health services—including leadership in telemedicine and strategic investments in online healthcare platforms—positions it at the forefront of an Australian sector undergoing rapid digital transformation. ESG and sustainability commitments further enhance its long-term appeal in a capital market increasingly focused on responsibility and transparency.
Positive demographic trends, ongoing regulatory tailwinds promoting supplemental private health coverage, and further enhancements to operational efficiency (leveraging AI, big data, and customer-focused apps) all present tangible upside triggers. Looking ahead, the next major results announcement (scheduled for 28 August 2025) offers a timely focal point that could act as a catalyst for renewed buying momentum.
Investment strategies
Medibank Private appears ideally suited to a spectrum of investment strategies, from short-term tactical positions to long-term portfolio building. For short- and medium-term traders, the current technical structure and confirmation of bullish momentum signals provide an opportunity to enter at stabilised levels with clearly defined support points (AUD 4.86) and near-term resistance targets (AUD 5.16+). Fundamentally driven investors may see the current price as an attractive entry, given robust growth forecasts, ongoing dividend payments, and the structural transformation of the business.
Long-term investors, in particular, could benefit from Medibank Private’s compounding growth and ongoing innovations in digital healthcare. The company’s strong brand recognition, rising institutional ownership (46.09%), and relentless focus on tech-led service diversification provide a unique platform for steady value accretion.
Is it the right time to buy Medibank Private?
In summary, Medibank Private stands out as a compelling candidate for positive revaluation in the months ahead. Its rare blend of robust earnings growth, low volatility (beta 0.12), sector-leading innovation, and high liquidity all point to a stock entering a promising new bullish phase. As the Australian health insurance industry undergoes transformation, Medibank Private’s strategic investments, steady dividend yield, and dominance in digital services seem to represent an excellent opportunity for investors seeking a solid balance of growth and stability. With strong upward momentum and defining catalysts on the horizon, Medibank Private may indeed be positioning itself as an institutional-quality growth stock for the new decade—one that deserves serious consideration as a potential cornerstone of an Australian equity portfolio.
How to buy Medibank Private stock in Australia
Buying Medibank Private stock online is now both simple and secure for Australian investors. All you need is an account with a regulated broker, which ensures safety and transparency. You can choose between two main methods: buying the shares outright for direct ownership (“spot buying”) or trading Contracts for Difference (CFDs) to benefit from leverage and flexible strategies. Each method has its advantages and fees. To help you make the best choice, a detailed broker comparison is provided further down the page.
Spot buying
When you buy Medibank Private shares with cash, you become an outright shareholder—eligible for dividends, voting rights, and long-term growth. In Australia, brokers typically charge a fixed commission per order, usually around $5 to $10 AUD.
Gain scenario
If the Medibank Private share price is $4.97 AUD, you can buy around 200 shares with a $1,000 stake, including a brokerage fee of around $5.
If the share price rises by 10%, your shares are now worth $1,100.
Result: +$100 gross gain, i.e. +10% on your investment.
This method suits investors seeking stability, transparency, and potential dividend income.
Trading via CFD
CFDs (Contracts for Difference) allow you to speculate on Medibank Private’s price without owning the underlying shares. CFD trading is popular for its leverage: you can control a larger position with less capital. Main fees include the spread (difference between buy/sell price) and overnight financing if you keep positions open for several days.
Gain Scenario: CFD with 5x Leverage
You open a CFD position on Medibank Private shares, with 5x leverage. This gives you a market exposure of $5,000.
✔️ Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%.
Result: +$400 gain, on a bet of $1,000 (excluding fees).
CFDs are ideal for short-term trading or taking advantage of market volatility, but higher gains carry greater risk.
Final advice
Before you invest, always compare brokers’ commissions, platform features, and access to both spot and CFD trading—our broker comparison lower on the page can help. Remember, the right buying method depends on your investment goals, risk tolerance, and preferred approach—whether you favour direct ownership or more active trading strategies.
Check out the best brokers in Australia!Compare brokersOur 7 tips for buying Medibank Private stock
| 📊 Step | 📝 Specific tip for Medibank Private |
|---|---|
| Analyze the market | Assess trends in private health insurance, considering government policy and Medibank Private’s market leadership in Australia. |
| Choose the right trading platform | Select an ASX-accredited broker with competitive fees to efficiently access Medibank Private shares. |
| Define your investment budget | Determine a budget that aligns with your financial goals, factoring in Medibank Private's strong but steady growth. |
| Choose a strategy (short or long term) | Consider a long-term approach, leveraging Medibank Private’s track record of dividend payments and digital health expansion. |
| Monitor news and financial results | Keep up with Medibank Private’s result announcements and updates about healthcare innovation or regulatory changes. |
| Use risk management tools | Set stop-loss orders or price alerts to manage your risk, especially around major earnings announcements for Medibank Private. |
| Sell at the right time | Look to realise gains when Medibank Private reaches new highs or after positive surprises in its financial results. |
The latest news about Medibank Private
Medibank Private reached a fresh 52-week high of 5.31 AUD in early July 2025. This achievement reflects positive investor sentiment and strong price momentum, underpinned by Medibank Private’s local leadership and strategic expansion in the Australian health insurance sector. The market recognised the company’s performance and trajectory, further boosting confidence in its growth outlook.
Technical indicators continue to send favourable signals for Medibank Private’s share price. The stock displays a confirmed Golden Cross with all major moving averages generating buy signals, while the RSI at 54.23 and a positive MACD reinforce the bullish trend. Immediate technical support stands at 4.86 AUD and resistance at 5.16 AUD, supporting potential for continued upward movement.
Recent half-year financials surpassed analyst expectations with robust operational profit growth of 12.5%. Medibank Private posted revenue of 4.27 billion AUD and operating profit of 386.8 million AUD in the latest half, outperforming consensus forecasts. This was accompanied by a solid dividend payout and confirmed the company’s ability to adapt to cost pressures while maintaining profitability.
Ongoing digital transformation and telehealth innovation strengthen Medibank Private’s competitive edge in Australia. Under CEO David Koczkar, initiatives in digital health and expanded telemedicine offerings have reinforced Medibank Private’s market leadership and improved customer engagement. These advancements are well-aligned with evolving health care consumer preferences in Australia, positioning the company for sustainable future growth.
The upcoming full-year results announcement on 28 August 2025 is expected to sustain market attention. Analysts and investors are closely watching this date for confirmation of positive trends. With steady earnings projections, a strong dividend history, and a focus on ESG initiatives, Medibank Private remains at the forefront of Australia’s health insurance and health services landscape.
FAQ
What is the latest dividend for Medibank Private stock?
Medibank Private currently pays a dividend, with the latest interim amounting to 0.17 AUD per share. This was paid following the ex-dividend date of 6 March 2025. Dividends are distributed regularly, and the yield is considered attractive for a leading health insurer. The company’s reliable distribution policy and steady growth in operating profit support consistent shareholder returns.
What is the forecast for Medibank Private stock in 2025, 2026, and 2027?
Based on the current price of 4.97 AUD, projected values are 6.46 AUD at the end of 2025, 7.46 AUD at the end of 2026, and 9.94 AUD at the end of 2027. Medibank Private’s strategic expansion in digital health, strong brand, and robust financial structure position it well for continued growth in Australia’s rising private health sector.
Should I sell my Medibank Private shares?
Holding Medibank Private shares may be beneficial due to the company’s defensive profile, proven ability to grow earnings, and sustained demand in private health insurance. Medibank Private’s low volatility, strong dividend history, and positive recent financial results further reinforce its long-term potential. For many investors, these fundamentals suggest that maintaining exposure to Medibank Private is a sound strategy.
Are Medibank Private dividends eligible for franking credits or special tax treatment in Australia?
Yes, Medibank Private dividends are typically franked, enabling Australian resident shareholders to receive franking credits that can offset income tax. Australian capital gains tax applies to the sale of shares held more than 12 months, with a discount available for individuals. There is no additional withholding tax for local investors, making the stock appealing for income-oriented portfolios.
What is the latest dividend for Medibank Private stock?
Medibank Private currently pays a dividend, with the latest interim amounting to 0.17 AUD per share. This was paid following the ex-dividend date of 6 March 2025. Dividends are distributed regularly, and the yield is considered attractive for a leading health insurer. The company’s reliable distribution policy and steady growth in operating profit support consistent shareholder returns.
What is the forecast for Medibank Private stock in 2025, 2026, and 2027?
Based on the current price of 4.97 AUD, projected values are 6.46 AUD at the end of 2025, 7.46 AUD at the end of 2026, and 9.94 AUD at the end of 2027. Medibank Private’s strategic expansion in digital health, strong brand, and robust financial structure position it well for continued growth in Australia’s rising private health sector.
Should I sell my Medibank Private shares?
Holding Medibank Private shares may be beneficial due to the company’s defensive profile, proven ability to grow earnings, and sustained demand in private health insurance. Medibank Private’s low volatility, strong dividend history, and positive recent financial results further reinforce its long-term potential. For many investors, these fundamentals suggest that maintaining exposure to Medibank Private is a sound strategy.
Are Medibank Private dividends eligible for franking credits or special tax treatment in Australia?
Yes, Medibank Private dividends are typically franked, enabling Australian resident shareholders to receive franking credits that can offset income tax. Australian capital gains tax applies to the sale of shares held more than 12 months, with a discount available for individuals. There is no additional withholding tax for local investors, making the stock appealing for income-oriented portfolios.
